MX2023002181A - Anticuerpos anti-ror1 y proteinas de union biespecificas relacionadas. - Google Patents

Anticuerpos anti-ror1 y proteinas de union biespecificas relacionadas.

Info

Publication number
MX2023002181A
MX2023002181A MX2023002181A MX2023002181A MX2023002181A MX 2023002181 A MX2023002181 A MX 2023002181A MX 2023002181 A MX2023002181 A MX 2023002181A MX 2023002181 A MX2023002181 A MX 2023002181A MX 2023002181 A MX2023002181 A MX 2023002181A
Authority
MX
Mexico
Prior art keywords
binding proteins
bispecific binding
ror1
ror1 antibodies
antibodies
Prior art date
Application number
MX2023002181A
Other languages
English (en)
Inventor
Danqing Wu
Rui Zhang
Xuan Wu
Shiyong Gong
Chengbin Wu
Kedong Ouyang
Original Assignee
Epimab Biotherapeutics Hk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimab Biotherapeutics Hk Ltd filed Critical Epimab Biotherapeutics Hk Ltd
Publication of MX2023002181A publication Critical patent/MX2023002181A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Abstract

La presente invención se refiere a nuevos anticuerpos que reconocen el receptor huérfano tipo tirosina quinasa del receptor 1 (ROR1) y proteínas de unión biespecíficas de ROR1/CD3 tales como proteínas de unión FIT-Ig y MAT-Fab fabricadas usando esos anticuerpos. Los anticuerpos y las proteínas de unión biespecíficas son útiles para el tratamiento de enfermedades tales como cánceres hematopoyéticos y tumores sólidos.
MX2023002181A 2020-08-24 2021-08-23 Anticuerpos anti-ror1 y proteinas de union biespecificas relacionadas. MX2023002181A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020110841 2020-08-24
CN2020141398 2020-12-30
PCT/CN2021/114088 WO2022042488A1 (en) 2020-08-24 2021-08-23 Anti-ror1 antibodies and related bispecific binding proteins

Publications (1)

Publication Number Publication Date
MX2023002181A true MX2023002181A (es) 2023-03-02

Family

ID=77946069

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002181A MX2023002181A (es) 2020-08-24 2021-08-23 Anticuerpos anti-ror1 y proteinas de union biespecificas relacionadas.

Country Status (12)

Country Link
US (1) US20240010753A1 (es)
EP (1) EP4200336A1 (es)
JP (1) JP2023538945A (es)
KR (1) KR20230053602A (es)
CN (2) CN113480656B (es)
AU (1) AU2021334677A1 (es)
BR (1) BR112023002895A2 (es)
CA (1) CA3190117A1 (es)
IL (1) IL300760A (es)
MX (1) MX2023002181A (es)
TW (1) TW202227491A (es)
WO (1) WO2022042488A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519251B2 (en) * 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2018035084A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
CN114539411B (zh) * 2022-04-29 2022-11-11 山东博安生物技术股份有限公司 一种ror1抗体或其抗原结合片段
US20230310605A1 (en) 2021-10-28 2023-10-05 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
WO2023186100A1 (zh) * 2022-04-02 2023-10-05 山东先声生物制药有限公司 抗ror1的抗体及其用途
WO2024014930A1 (ko) * 2022-07-15 2024-01-18 에이비엘바이오 주식회사 항-ror1 항체, 이를 포함하는 이중특이성 항체, 및 이들의 용도
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242014B2 (en) * 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
WO2017053469A2 (en) * 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
EA201891066A1 (ru) * 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ Антитела к ror1
AU2017209099A1 (en) * 2016-01-22 2018-08-02 Janssen Biotech, Inc. Anti-ROR1 antibodies, ROR1 x CD3 bispecific antibodies, and methods of using the same
WO2018035084A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
US20220096651A1 (en) * 2019-01-29 2022-03-31 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
CN111286512A (zh) * 2019-06-05 2020-06-16 南京艾德免疫治疗研究院有限公司 靶向人源化酪氨酸激酶孤儿受体1的嵌合抗原受体及其用途
CN114174339A (zh) * 2019-06-07 2022-03-11 阿迪马布有限责任公司 高亲和力抗cd3抗体及其产生和使用方法
JP2023504016A (ja) * 2019-11-26 2023-02-01 シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質

Also Published As

Publication number Publication date
CN114085288A (zh) 2022-02-25
US20240010753A1 (en) 2024-01-11
CN113480656A (zh) 2021-10-08
KR20230053602A (ko) 2023-04-21
AU2021334677A1 (en) 2023-03-02
EP4200336A1 (en) 2023-06-28
TW202227491A (zh) 2022-07-16
CA3190117A1 (en) 2022-03-03
JP2023538945A (ja) 2023-09-12
IL300760A (en) 2023-04-01
CN113480656B (zh) 2022-06-03
WO2022042488A1 (en) 2022-03-03
BR112023002895A2 (pt) 2023-03-21

Similar Documents

Publication Publication Date Title
MX2023002181A (es) Anticuerpos anti-ror1 y proteinas de union biespecificas relacionadas.
AU2018275359A1 (en) Antibodies specific for FLT3 and their uses
MX2021009087A (es) Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
MY194642A (en) Antibodies binding to cd3
PH12019502637A1 (en) Chimeric antigen receptors targeting flt3
MX2019015349A (es) Anticuerpos biespecificos para receptor 1 huerfano tipo receptor de tirosina cinasa (ror1) y grupo de diferenciacion 3 (cd3).
MX2022001049A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
MX2022007288A (es) Agentes de union a ilt3 y metodos de uso de los mismos.
WO2020139926A3 (en) Anti-ctla4 antibodies and methods of use thereof
MX2021011750A (es) Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos.
MX2022013466A (es) Agentes de union a ilt y metodos para su uso.
MX2022002524A (es) Formulaciones farmaceuticas y regimenes de dosificacion para proteinas de union multiespecificas que se unen a her2, nkg2d y cd16 para el tratamiento del cancer.
WO2021048564A3 (en) Antigen-binding domain
GB2596001A8 (en) Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class 1-like protein (OMCP) and tumor-specific binding partner
MX2022016544A (es) Agentes de union a lair-1 y metodos para su uso.
WO2019020774A3 (en) NOVEL ANTIBODIES AND COMBINED USE OF ANTIBODY THAT INDUCES TREG DEPLOYMENT AND AN IMMUNOSTIMULATOR ANTIBODY
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2022015204A (es) Anticuerpos que se unen a cd3.
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2023008518A (es) Anticuerpos anti-kit y usos de los mismos.
MX2019009619A (es) Anticuerpo anti-cancer convertible de celula t regulatoria inducible por ifn-gamma (irtca) y usos del mismo.
MX2022002363A (es) Sistema receptor de antígeno quimérico y usos de este.
MX2023001555A (es) Proteinas que se unen a nkg2d, cd16 y egfr.